After-Hours Movers

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) 25.3% HIGHER; today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 2010 Gastrointestinal Cancers Symposium that took place in Orlando, Florida from January 22 to 24, 2010. The clinical trial is a Phase 1/2, three arm, multicenter, dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine or docetaxel or pemetrexed in patients with advanced solid tumors. The results of the trial discussed only those patients who were treated for gastrointestinal cancer which included but were not limited to cancers of the pancreas, colon and bile duct. Click here to see the full report.

VMware, Inc. (NYSE: VMW) 17.5% HIGHER; reports Q4 EPS of $0.31, 5 cents better than the analyst estimate of $0.26. Revenue for the quarter was $608 maillioin, which compares to the ...

Icagen, Inc. (Nasdaq: ICGN) 41% LOWER; reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.

Entropic Communications, Inc. (NASDAQ: ENTR) 11.4% HIGHER; reports Q3 EPS of $0.02, 1 cent better than the analyst estimate of $0.01. Revenue for the quarter was $31.0 million, which compares to the estimate of $29.55 million.

Zoran Corporation (NASDAQ: ZRAN) 11.3% LOWER; reports Q3 EPS of $0.17, cents better than the analyst estimate of $0.04. Revenue for the quarter was $115.5 million, which compares to the estimate of $109.19 million. Sees Q4 loss of $0.00-$0.07, versus $0.01 EPS. Sees Q4 revenues of $91-$95 million, versus the consensus of $108 million.

Baidu, Inc. (Nasdaq: BIDU) 11.1% LOWER; reports Q3 EPS of ...